Predictive value of LDH kinetics in bevacizumab treatment and survival of patients with advanced NSCLC

BACKGROUND: The combination of bevacizumab and chemotherapy is still one of the standard treatments for advanced non-small-cell lung cancer (NSCLC) patients in the new era of targeted therapy. Although a high level of baseline lactate dehydrogenase (LDH) was found to predict survival benefit from be...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Butuo, Li, Cheng, Guo, Meiying, Shang, Shuheng, Li, Xiaogang, Xie, Peng, Sun, Xindong, Yu, Jinming, Wang, Linlin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6166744/
https://www.ncbi.nlm.nih.gov/pubmed/30310292
http://dx.doi.org/10.2147/OTT.S171566

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6166744/
https://www.ncbi.nlm.nih.gov/pubmed/30310292
http://dx.doi.org/10.2147/OTT.S171566

Ejemplares similares